Efficacy of COVID-HIGIV in animal models of SARS-CoV-2 infection

Sci Rep. 2022 Oct 10;12(1):16956. doi: 10.1038/s41598-022-21223-2.


In late 2019 the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus emerged in China and quickly spread into a worldwide pandemic. It has caused millions of hospitalizations and deaths, despite the use of COVID-19 vaccines. Convalescent plasma and monoclonal antibodies emerged as major therapeutic options for treatment of COVID-19. We have developed an anti-SARS-CoV-2 immunoglobulin intravenous (Human) (COVID-HIGIV), a potential improvement from using convalescent plasma. In this report the efficacy of COVID-HIGIV was evaluated in hamster and mouse models of SARS-CoV-2 infection. COVID-HIGIV treatment in both mice and hamsters significantly reduced the viral load in the lungs. Among COVID-HIGIV treated animals, infection-related body weight loss was reduced and the animals regained their baseline body weight faster than the PBS controls. In hamsters, COVID-HIGIV treatment reduced infection-associated lung pathology including lung inflammation, and pneumocyte hypertrophy in the lungs. These results support ongoing trials for outpatient treatment with COVID-HIGIV for safety and efficacy evaluation (NCT04910269, NCT04546581).

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Antibodies, Monoclonal
  • COVID-19 Serotherapy
  • COVID-19 Vaccines
  • COVID-19* / therapy
  • Clinical Trials as Topic
  • Cricetinae
  • Disease Models, Animal
  • Humans
  • Immunization, Passive
  • Lung / pathology
  • Mice
  • SARS-CoV-2


  • Antibodies, Monoclonal
  • COVID-19 Vaccines

Associated data

  • ClinicalTrials.gov/NCT04910269
  • ClinicalTrials.gov/NCT04546581